Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Transwell migration assays were performed with

    2020-03-24


    Transwell migration assays were performed with SKOV3 (A) and OVISE (B) AR-13324 following transfection with control vector pcDNA3.1 or E-cadherin vector for 48 h prior to treatment without (Ctrl) or with 100 ng/mL activin A (Act A) for 24 h. The upper panels show re-presentative photomicrographs and the lower panels show summarized quantitative results. Results are expressed as the mean ± SEM of at least three independent experiments and values without a common
    Acknowledgement
    This work was supported by a Foundation Grant from the Canadian Institutes of Health Research to P.C.K.L (#143317).
    References
    [9] M. Dean, D.A. Davis, J.E. Burdette, Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-ca-nonical signaling, Cancer Lett. 391 (2017) 114–124.
    [15] J.C. Cheng, C. Klausen, P.C. Leung, Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells, Cancer Lett. 329 (2013) 197–206.
    F. Portillo, M.A. Nieto, The transcription factor snail controls epithelial-mesench-ymal transitions by repressing E-cadherin expression, Nat. Cell Biol. 2 (2000) 76–83.
    [18] V. Bolos, H. Peinado, M.A. Perez-Moreno, M.F. Fraga, M. Esteller, A. Cano, The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors, J. Cell Sci. 116 (2003) 499–511.
    [19] K.A. Brown, J.A. Pietenpol, H.L. Moses, A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling, J. Cell. Biochem. 101 (2007) 9–33. [20] H.A. Loomans, C.D. Andl, Intertwining of activin a and TGFbeta signaling: dual roles in cancer progression and cancer cell invasion, Cancers 7 (2014) 70–91. [21] I. Ito, T. Minegishi, J. Fukuda, H. Shinozaki, N. Auersperg, P.C. Leung, Presence of activin signal transduction in normal ovarian cells and epithelial ovarian  Experimental Cell Research xxx (xxxx) xxx–xxx
    [24] N. Di Simone, W.F. Crowley Jr., Q.F. Wang, P.M. Sluss, A.L. Schneyer, Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation, Endocrinology 137 (1996) 486–494.
    T.K. Woodruff, Virtual high-throughput screening to identify novel activin an-tagonists, J. Med. Chem. 58 (2015) 5637–5648. [41] J.J. Tao, N.A. Cangemi, V. Makker, K. Cadoo, J.F. Liu, D.W. Rasco, W.H. Navarro, C.M. Haqq, D.M. Hyman, First-in-Human phase I study of the activin a inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors, Clinical cancer research : an official journal of the American Association for Cancer Research, (2019).
    ARTICLES
    Acute Kidney Injury in Pediatric Cancer Patients
    Objective To analyze the incidence of acute kidney injury (AKI) in the first year after cancer diagnosis in children and to evaluate the short-term and long-term effects on renal function and proteinuria.
    Study design Retrospective review of medical records was done on children who were diagnosed and treated for cancer at Seoul National University Hospital between 2004 and 2013. AKI was defined according to the Kidney Disease: Improving Global Outcomes criteria. Impaired renal function of estimated glomerular filtration rate less than 90 mL/minute/1.73 m2 and development of proteinuria of cancer survivors were also assessed.
    Results This study included 1868 patients who were diagnosed with cancer at a median age of 7.9 years. During the course of treatment, 983 patients (52.6%) developed 1864 episodes of AKI, and the cumulative incidence at 2 weeks, 3 months, and 1 year after diagnosis was 28.9%, 39.6%, and 53.6%, respectively. The 1-year cumulative incidence was the highest in patients with acute myeloid leukemias (88.4%). In all, 6.1% of patients had more than 4 episodes of AKI and 11.8% of patients had stage 3 AKI. Among the 1096 childhood cancer survivors, 22.6% were found to have impaired renal function. A greater number of AKI episodes (³4 times) and nephrectomy were independent risk factors of impaired renal function. Also, 8.2% of the survivors developed proteinuria among 742 childhood cancer survivors.